CompletedPhase 3

A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Japan

Plain-language summary

The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)

Who can participate

Age range20 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Japanese SCD patients with ataxia (Experience of clinical trials of KPS-0373) Exclusion Criteria: * Patients with secondary ataxia * Patients with clinically significant hepatic, renal, or cardiovascular dysfunction * Discontinuations in another clinical trials caused by side effects

What they're measuring

SARA (Scale for the Assessment and Rating of Ataxia)

Timeframe: 24 weeks

Trial details

NCT IDNCT01970137

SponsorKissei Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2014-10

View on ClinicalTrials.gov More Spinocerebellar Degeneration trials